SUVmax during 18FDG-PET scanning in small cell lung cancer: Similar information as in non-small cell lung cancer?
Abstract In patients with non-small cell lung carcinoma (NSCLC) fluorine-18 fluorodeoxyglucose positron emission tomography (18FDG-PET)-scanning is shown to be of prognostic value. Small cell lung cancer (SCLC) is an aggressive tumor with poor prognosis. Limited results on the prognostic and predict...
Gespeichert in:
| Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2012-04, Vol.76 (1), p.67-71 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 71 |
|---|---|
| container_issue | 1 |
| container_start_page | 67 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 76 |
| creator | van der Leest, C Smit, E.F Baas, J Versteijlen, R.J van Walree, N Hoogsteden, H.C Aerts, J.G.J.V |
| description | Abstract In patients with non-small cell lung carcinoma (NSCLC) fluorine-18 fluorodeoxyglucose positron emission tomography (18FDG-PET)-scanning is shown to be of prognostic value. Small cell lung cancer (SCLC) is an aggressive tumor with poor prognosis. Limited results on the prognostic and predictive value of the maximum standard uptake values (SUVmax ) obtained during 18FDG-PET scanning in SCLC are available. An observational study in 75 chemonaive patients diagnosed with SCLC who underwent a 18FDG-PET scan was performed. SUVmax values of the primary tumor were related to the overall survival (OS) and the progression free survival (PFS). Significant lower SUVmax values of the primary tumor were observed in patients with stage I–III disease compared to stage IV disease. SUVmax did not discriminate for either OS or PFS in the whole group of patients. In patients with stage IV disease and treatment with chemotherapy, OS and PFS were significantly higher in patients with a high SUVmax . ( p -value 0.005 and 0.002 respectively) compared to patients with a low SUVmax value. In patients with SCLC metabolic activity determined using 18FDG-PET (SUVmax ) differed between stage I–III and stage IV diseases. Compared to NSCLC, the relationship between SUVmax and prognosis seems more complex. |
| doi_str_mv | 10.1016/j.lungcan.2011.09.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_927832458</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0169500211004764</els_id><sourcerecordid>927832458</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-4ce3e126d5afdb9fda64fb1c139eed4c32fdaf0c77febb37cb67e12b21d13fc3</originalsourceid><addsrcrecordid>eNqFkl1rFDEUhoNY7Fr9CcrciFczPSeZmUy8sEhtq1BQ2NXbkMlHyTqTaZOd0v57M-yqIII3CSTPe87h4RDyCqFCwPZ0Ww1zuNEqVBQQKxAVAH9CVthxWnaM0adklTlRNgD0mDxPaQuAHEE8I8cUhWihEytyt_72fVQPhZmjDzcFdpcfr8qvF5si5dJhefKhSKMahkLbfCxNi_ylbXxXrP3oBxUz4qY4qp2fQqHSkghTKP-dOntBjpwakn15uE_I5vJic_6pvP5y9fn8w3Wp67rZlbW2zCJtTaOc6YUzqq1djxqZsNbUmtH85EBz7mzfM677lme-p2iQOc1OyNt92ds43c027eTo0zKMCnaakxSUd4zWTZfJZk_qOKUUrZO30Y8qPkoEubiWW3lwLRfXEoTMrnPu9aHD3I_W_E79kpuBNwdAZZuDi1mAT3-4pm1bTlnmzvaczTruvY0yaW-zLOOj1TtpJv_fUd7_VUEPPvjc9Id9tGk7zTFk1xJlohLkelmMZS8QAWre1uwnu7m1gA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>927832458</pqid></control><display><type>article</type><title>SUVmax during 18FDG-PET scanning in small cell lung cancer: Similar information as in non-small cell lung cancer?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>van der Leest, C ; Smit, E.F ; Baas, J ; Versteijlen, R.J ; van Walree, N ; Hoogsteden, H.C ; Aerts, J.G.J.V</creator><creatorcontrib>van der Leest, C ; Smit, E.F ; Baas, J ; Versteijlen, R.J ; van Walree, N ; Hoogsteden, H.C ; Aerts, J.G.J.V</creatorcontrib><description>Abstract In patients with non-small cell lung carcinoma (NSCLC) fluorine-18 fluorodeoxyglucose positron emission tomography (18FDG-PET)-scanning is shown to be of prognostic value. Small cell lung cancer (SCLC) is an aggressive tumor with poor prognosis. Limited results on the prognostic and predictive value of the maximum standard uptake values (SUVmax ) obtained during 18FDG-PET scanning in SCLC are available. An observational study in 75 chemonaive patients diagnosed with SCLC who underwent a 18FDG-PET scan was performed. SUVmax values of the primary tumor were related to the overall survival (OS) and the progression free survival (PFS). Significant lower SUVmax values of the primary tumor were observed in patients with stage I–III disease compared to stage IV disease. SUVmax did not discriminate for either OS or PFS in the whole group of patients. In patients with stage IV disease and treatment with chemotherapy, OS and PFS were significantly higher in patients with a high SUVmax . ( p -value 0.005 and 0.002 respectively) compared to patients with a low SUVmax value. In patients with SCLC metabolic activity determined using 18FDG-PET (SUVmax ) differed between stage I–III and stage IV diseases. Compared to NSCLC, the relationship between SUVmax and prognosis seems more complex.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2011.09.007</identifier><identifier>PMID: 21996089</identifier><identifier>CODEN: LUCAE5</identifier><language>eng</language><publisher>Oxford: Elsevier Ireland Ltd</publisher><subject>18FDG-PET ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - diagnostic imaging ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - therapy ; Female ; Fluorodeoxyglucose F18 ; Follow-Up Studies ; Hematology, Oncology and Palliative Medicine ; Humans ; Lung Neoplasms - diagnostic imaging ; Lung Neoplasms - mortality ; Lung Neoplasms - therapy ; Male ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Overall survival ; Pneumology ; Positron-Emission Tomography ; Prognosis ; Progression free survival ; Pulmonary/Respiratory ; Radiopharmaceuticals ; Small cell lung cancer ; Small Cell Lung Carcinoma - diagnostic imaging ; Small Cell Lung Carcinoma - mortality ; Small Cell Lung Carcinoma - therapy ; Stage IV disease ; Survival Rate ; SUVmax ; Tumors ; Tumors of the respiratory system and mediastinum</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2012-04, Vol.76 (1), p.67-71</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2011 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-4ce3e126d5afdb9fda64fb1c139eed4c32fdaf0c77febb37cb67e12b21d13fc3</citedby><cites>FETCH-LOGICAL-c445t-4ce3e126d5afdb9fda64fb1c139eed4c32fdaf0c77febb37cb67e12b21d13fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lungcan.2011.09.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25666723$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21996089$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van der Leest, C</creatorcontrib><creatorcontrib>Smit, E.F</creatorcontrib><creatorcontrib>Baas, J</creatorcontrib><creatorcontrib>Versteijlen, R.J</creatorcontrib><creatorcontrib>van Walree, N</creatorcontrib><creatorcontrib>Hoogsteden, H.C</creatorcontrib><creatorcontrib>Aerts, J.G.J.V</creatorcontrib><title>SUVmax during 18FDG-PET scanning in small cell lung cancer: Similar information as in non-small cell lung cancer?</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>Abstract In patients with non-small cell lung carcinoma (NSCLC) fluorine-18 fluorodeoxyglucose positron emission tomography (18FDG-PET)-scanning is shown to be of prognostic value. Small cell lung cancer (SCLC) is an aggressive tumor with poor prognosis. Limited results on the prognostic and predictive value of the maximum standard uptake values (SUVmax ) obtained during 18FDG-PET scanning in SCLC are available. An observational study in 75 chemonaive patients diagnosed with SCLC who underwent a 18FDG-PET scan was performed. SUVmax values of the primary tumor were related to the overall survival (OS) and the progression free survival (PFS). Significant lower SUVmax values of the primary tumor were observed in patients with stage I–III disease compared to stage IV disease. SUVmax did not discriminate for either OS or PFS in the whole group of patients. In patients with stage IV disease and treatment with chemotherapy, OS and PFS were significantly higher in patients with a high SUVmax . ( p -value 0.005 and 0.002 respectively) compared to patients with a low SUVmax value. In patients with SCLC metabolic activity determined using 18FDG-PET (SUVmax ) differed between stage I–III and stage IV diseases. Compared to NSCLC, the relationship between SUVmax and prognosis seems more complex.</description><subject>18FDG-PET</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - therapy</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Follow-Up Studies</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Lung Neoplasms - diagnostic imaging</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Overall survival</subject><subject>Pneumology</subject><subject>Positron-Emission Tomography</subject><subject>Prognosis</subject><subject>Progression free survival</subject><subject>Pulmonary/Respiratory</subject><subject>Radiopharmaceuticals</subject><subject>Small cell lung cancer</subject><subject>Small Cell Lung Carcinoma - diagnostic imaging</subject><subject>Small Cell Lung Carcinoma - mortality</subject><subject>Small Cell Lung Carcinoma - therapy</subject><subject>Stage IV disease</subject><subject>Survival Rate</subject><subject>SUVmax</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkl1rFDEUhoNY7Fr9CcrciFczPSeZmUy8sEhtq1BQ2NXbkMlHyTqTaZOd0v57M-yqIII3CSTPe87h4RDyCqFCwPZ0Ww1zuNEqVBQQKxAVAH9CVthxWnaM0adklTlRNgD0mDxPaQuAHEE8I8cUhWihEytyt_72fVQPhZmjDzcFdpcfr8qvF5si5dJhefKhSKMahkLbfCxNi_ylbXxXrP3oBxUz4qY4qp2fQqHSkghTKP-dOntBjpwakn15uE_I5vJic_6pvP5y9fn8w3Wp67rZlbW2zCJtTaOc6YUzqq1djxqZsNbUmtH85EBz7mzfM677lme-p2iQOc1OyNt92ds43c027eTo0zKMCnaakxSUd4zWTZfJZk_qOKUUrZO30Y8qPkoEubiWW3lwLRfXEoTMrnPu9aHD3I_W_E79kpuBNwdAZZuDi1mAT3-4pm1bTlnmzvaczTruvY0yaW-zLOOj1TtpJv_fUd7_VUEPPvjc9Id9tGk7zTFk1xJlohLkelmMZS8QAWre1uwnu7m1gA</recordid><startdate>20120401</startdate><enddate>20120401</enddate><creator>van der Leest, C</creator><creator>Smit, E.F</creator><creator>Baas, J</creator><creator>Versteijlen, R.J</creator><creator>van Walree, N</creator><creator>Hoogsteden, H.C</creator><creator>Aerts, J.G.J.V</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120401</creationdate><title>SUVmax during 18FDG-PET scanning in small cell lung cancer: Similar information as in non-small cell lung cancer?</title><author>van der Leest, C ; Smit, E.F ; Baas, J ; Versteijlen, R.J ; van Walree, N ; Hoogsteden, H.C ; Aerts, J.G.J.V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-4ce3e126d5afdb9fda64fb1c139eed4c32fdaf0c77febb37cb67e12b21d13fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>18FDG-PET</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - therapy</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Follow-Up Studies</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Lung Neoplasms - diagnostic imaging</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Overall survival</topic><topic>Pneumology</topic><topic>Positron-Emission Tomography</topic><topic>Prognosis</topic><topic>Progression free survival</topic><topic>Pulmonary/Respiratory</topic><topic>Radiopharmaceuticals</topic><topic>Small cell lung cancer</topic><topic>Small Cell Lung Carcinoma - diagnostic imaging</topic><topic>Small Cell Lung Carcinoma - mortality</topic><topic>Small Cell Lung Carcinoma - therapy</topic><topic>Stage IV disease</topic><topic>Survival Rate</topic><topic>SUVmax</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van der Leest, C</creatorcontrib><creatorcontrib>Smit, E.F</creatorcontrib><creatorcontrib>Baas, J</creatorcontrib><creatorcontrib>Versteijlen, R.J</creatorcontrib><creatorcontrib>van Walree, N</creatorcontrib><creatorcontrib>Hoogsteden, H.C</creatorcontrib><creatorcontrib>Aerts, J.G.J.V</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van der Leest, C</au><au>Smit, E.F</au><au>Baas, J</au><au>Versteijlen, R.J</au><au>van Walree, N</au><au>Hoogsteden, H.C</au><au>Aerts, J.G.J.V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SUVmax during 18FDG-PET scanning in small cell lung cancer: Similar information as in non-small cell lung cancer?</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2012-04-01</date><risdate>2012</risdate><volume>76</volume><issue>1</issue><spage>67</spage><epage>71</epage><pages>67-71</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><coden>LUCAE5</coden><abstract>Abstract In patients with non-small cell lung carcinoma (NSCLC) fluorine-18 fluorodeoxyglucose positron emission tomography (18FDG-PET)-scanning is shown to be of prognostic value. Small cell lung cancer (SCLC) is an aggressive tumor with poor prognosis. Limited results on the prognostic and predictive value of the maximum standard uptake values (SUVmax ) obtained during 18FDG-PET scanning in SCLC are available. An observational study in 75 chemonaive patients diagnosed with SCLC who underwent a 18FDG-PET scan was performed. SUVmax values of the primary tumor were related to the overall survival (OS) and the progression free survival (PFS). Significant lower SUVmax values of the primary tumor were observed in patients with stage I–III disease compared to stage IV disease. SUVmax did not discriminate for either OS or PFS in the whole group of patients. In patients with stage IV disease and treatment with chemotherapy, OS and PFS were significantly higher in patients with a high SUVmax . ( p -value 0.005 and 0.002 respectively) compared to patients with a low SUVmax value. In patients with SCLC metabolic activity determined using 18FDG-PET (SUVmax ) differed between stage I–III and stage IV diseases. Compared to NSCLC, the relationship between SUVmax and prognosis seems more complex.</abstract><cop>Oxford</cop><pub>Elsevier Ireland Ltd</pub><pmid>21996089</pmid><doi>10.1016/j.lungcan.2011.09.007</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2012-04, Vol.76 (1), p.67-71 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_927832458 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | 18FDG-PET Aged Aged, 80 and over Biological and medical sciences Carcinoma, Non-Small-Cell Lung - diagnostic imaging Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - therapy Female Fluorodeoxyglucose F18 Follow-Up Studies Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - diagnostic imaging Lung Neoplasms - mortality Lung Neoplasms - therapy Male Medical sciences Middle Aged Neoplasm Staging Overall survival Pneumology Positron-Emission Tomography Prognosis Progression free survival Pulmonary/Respiratory Radiopharmaceuticals Small cell lung cancer Small Cell Lung Carcinoma - diagnostic imaging Small Cell Lung Carcinoma - mortality Small Cell Lung Carcinoma - therapy Stage IV disease Survival Rate SUVmax Tumors Tumors of the respiratory system and mediastinum |
| title | SUVmax during 18FDG-PET scanning in small cell lung cancer: Similar information as in non-small cell lung cancer? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T20%3A29%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SUVmax%20during%2018FDG-PET%20scanning%20in%20small%20cell%20lung%20cancer:%20Similar%20information%20as%20in%20non-small%20cell%20lung%20cancer?&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=van%20der%20Leest,%20C&rft.date=2012-04-01&rft.volume=76&rft.issue=1&rft.spage=67&rft.epage=71&rft.pages=67-71&rft.issn=0169-5002&rft.eissn=1872-8332&rft.coden=LUCAE5&rft_id=info:doi/10.1016/j.lungcan.2011.09.007&rft_dat=%3Cproquest_cross%3E927832458%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=927832458&rft_id=info:pmid/21996089&rft_els_id=1_s2_0_S0169500211004764&rfr_iscdi=true |